Landscapes / Companies
Alexion Pharmaceuticals, Inc. not checked
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
5 approved
4 in Phase 3
Drugs
15
in active trials · 38 in all
Trials
30 active
158 since 2021
Drugs15
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Complement inhibitor |
Approved | 7 Dec 2026soonPhase 3 trial completes | |||
| How it works | Blocks part of the complement system | ||||
| Next date | 7 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | NMOSD, Neuromyelitis Optica Spectrum Disorders | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | 15 Dec 2026soonPhase 3 trial completes | |||
| How it works | An antibody | ||||
| Next date | 15 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Generalized Myasthenia Gravis, gMG | ||||
| Open drug page | |||||
Complement factor D inhibitor |
Approved | 28 May 2027Phase 3 trial completes | |||
| Next date | 28 May 2027 · Phase 3 trial completes | ||||
| Also tested for | Paroxysmal Nocturnal Hemoglobinuria, PNH and 1 more | ||||
| Open drug page | |||||
Complement inhibitor |
Approved | 25 Jun 2027Phase 4 trial completes | |||
| How it works | Blocks part of the complement system | ||||
| Next date | 25 Jun 2027 · Phase 4 trial completes | ||||
| Also tested for | Generalized Myasthenia Gravis, gMG and 13 more | ||||
| Open drug page | |||||
Transthyretin stabilizer |
Approved in Japan | 31 Mar 2028Phase 4 trial completes | |||
| Next date | 31 Mar 2028 · Phase 4 trial completes | ||||
| Also tested for | Transthyretin-type Cardiac Amyloidosis | ||||
| Open drug page | |||||
— |
Phase 3 | 6 Dec 2027Phase 3 trial completes | |||
| Next date | 6 Dec 2027 · Phase 3 trial completes | ||||
| Also tested for | Transthyretin Amyloid Cardiomyopathy (ATTR-CM), Transthyretin Amyloid Cardiomyopathy and 1 more | ||||
| Open drug page | |||||
— |
Phase 3 | — | |||
| Also tested for | Hypophosphatasia | ||||
| Open drug page | |||||
— |
Phase 3 | — | |||
| Also tested for | AL Amyloidosis | ||||
| Open drug page | |||||
— |
Phase 3 | — | |||
| Also tested for | Chronic Hypoparathyroidism, Endocrine System Diseases and 1 more | ||||
| Open drug page | |||||
— |
Phase 2 | 2 Jul 2027Phase 2 trial completes | |||
| Next date | 2 Jul 2027 · Phase 2 trial completes | ||||
| Also tested for | Primary Membranous Nephropathy | ||||
| Open drug page | |||||
— |
Phase 2 | 11 Oct 2027Phase 2 trial completes | |||
| Next date | 11 Oct 2027 · Phase 2 trial completes | ||||
| Also tested for | Antibody-Mediated Rejection, Kidney Transplantation and 2 more | ||||
| Open drug page | |||||
Multi-specific immunoglobulin |
Phase 2 | 11 Oct 2027Phase 2 trial completes | |||
| How it works | An antibody built to latch onto two or more targets at once | ||||
| Next date | 11 Oct 2027 · Phase 2 trial completes | ||||
| Also tested for | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | ||||
| Open drug page | |||||
— |
AstraZeneca |
Phase 1/2 | 15 Aug 2029Phase 1/2 trial completes | ||
| Next date | 15 Aug 2029 · Phase 1/2 trial completes | ||||
| Also tested for | Relapsed AL Amyloidosis, Refractory AL Amyloidosis and 2 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 27 Jan 2032Phase 1/2 trial completes | |||
| Next date | 27 Jan 2032 · Phase 1/2 trial completes | ||||
| Also tested for | BAG3 Mutation Associated Dilated Cardiomyopathy | ||||
| Open drug page | |||||
— |
Phase 1 | 9 Aug 2027Phase 1 trial completes | |||
| Next date | 9 Aug 2027 · Phase 1 trial completes | ||||
| Open drug page | |||||
No drugs match “”.
About
- No active trial
- 23 other drugs
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021